AstraZeneca: Atherosclerosis trials

The registry lists 21 Atherosclerosis studies with AstraZeneca as lead sponsor. 1 are open to participants now and 4 have results posted.

Early Phase 1 2Phase 1 5Phase 2 3Phase 3 5No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventRecruitingNCT07000357Phase 3
• Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial InfarctionCompletedNCT04610892Phase 2Results posted
• Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular DiseaseCompletedNCT03004638Phase 2Results posted
• A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical AtherosclerosisCompletedNCT02546323Phase 3Results posted
• 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With EzetimibeCompletedNCT00525824Phase 3Results posted
• A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventActive, not recruitingNCT07000123Phase 3
• A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With ObesityCompletedNCT06942923Phase 1
• A Study to Assess the Effect of AZD0780 on Ambulatory Blood PressureCompletedNCT06692764Phase 2
• A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.CompletedNCT06675175Phase 1
• Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes MellitusCompletedNCT03654313Phase 1
• Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884CompletedNCT03001297Phase 1
• Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery DiseaseCompletedNCT01554800Phase 1
• Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in SpainCompletedNCT00998062
• A Study on Intima Media Thickness (IMT) in Middle-aged SubjectsCompletedNCT00784264
• Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function MeasurementsCompletedNCT00783042Early Phase 1
• Effects of Crestor on Inflammation of Atherosclerotic PlaquesCompletedNCT00689416Early Phase 1
• Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary PreventionCompletedNCT00689377
• Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mgCompletedNCT00653445Phase 3
• Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsCompletedNCT00536965
• Percentage of Secondary Prevention Patients Treated to Their LDL-C TargetsCompletedNCT00536796
• Diabetic Under 70 (Diabetics Below 70)CompletedNCT00516204